Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Canada: Long-term COVID-19 associated with psychiatric symptoms and cognitive impairment, research recently published in the journal Brain, Behavior,...
Read Full NewsA yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.
A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.
The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.
1.
Single-dose radiation before surgery can eradicate breast cancer
2.
In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.
3.
Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer
4.
There has been a new target found that might stop blood cancer.
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
Molecular Matching for Hematologic Therapy Selection
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial
4.
Examining Serum Osmolality: What It Is And How To Test For It
5.
All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge